Valuation dashboard for Janux Therapeutics, Inc. (JANX) with P/E N/A, P/B 1.09, EV/EBITDA -11.59 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors.
Analysis Summary
Trailing-twelve-month margins: gross margin 68.9%, operating margin -450.3%, net margin -321.8%.
At the current price of $16.25, JANX has negative trailing earnings (P/E not meaningful) and an ROE of -10.79%. Market capitalisation stands at $991M.
Balance sheet quality for JANX: current ratio of 39.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.09 |
| EV / EBITDA | -11.59 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-2.95 |
| vs Current Price | -118.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | $991M | 1.09 | -10.8% | |
| CLDX | Celldex Therapeutics, Inc. | $2.6B | 4.25 | -52.4% | |
| IMNM | Immunome, Inc. | $2.2B | 5.06 | -50.6% | |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.4B | 13.49 | 2.45 | 20.1% |
| ABCL | AbCellera Biologics Inc. | $3.6B | 3.88 | -17.5% | |
| NUVB | Nuvation Bio Inc. | $2.0B | 7.68 | -66.9% |
Price
| Price | $16.25 |
| Market Cap | $991M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -10.79% |
| Return on Invested Capital | -15.11% |
| Return on Assets | -10.18% |
| Gross Margin | 68.91% |
| Operating Margin | -450.30% |
| Net Margin | -321.81% |
Related companies: ABCL · BHVN · CLDX · HRMY · IMNM · MAZE · NUVB
Explore sector: Healthcare · Biotechnology
More sections of JANX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks